Medical management of polymyalgia rheumatica

Bibliography

• Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454-61
   PubMed Web of Science ®Google Scholar
• Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672-80
   PubMed Web of Science ®Google Scholar
• Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984;13:322-8
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Rodríguez-Valverde V, Blanco R, Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med 1997;157:317-20
   PubMedGoogle Scholar
• González-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003;33:38-48
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Rheum Dis Clin North Am 2001;27:729-49
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Olivieri I, Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997;127:27-31
   PubMed Web of Science ®Google Scholar
• Cantini F, Salvarani C, Olivieri I, Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 2001;28:1049-55
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol 2005;23:462-8
   PubMed Web of Science ®Google Scholar
• Salvarani C, Barozzi L, Cantini F, Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis 2008;67:758-61
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Salvarani C, Schirmer M, ; members of the American College of Rheumatology Work Group for Development of Classification Criteria for PMR. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 2008;35:270-7
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000;27:2179-84
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998;25:1750-5
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004;33:289-93
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine 2005;84:269-76
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Miranda-Filloy JA, Martin J. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management. Drugs Aging 2006;23:627-49
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Vázquez-Caruncho M, The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999;26:1326-32
   PubMed Web of Science ®Google Scholar
• Kremers HM, Reinalda MS, Crowson CS, Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005;32:65-73
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970 – 1991. Arthritis Rheum 1995;38:369-73
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Hunder GG. Diagnostic approach in a patient presenting with polymyalgia. Clin Exp Rheumatol 1999;17:276-8
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay M. The diagnosis and management of patients with giant cell arteritis. J Rheumatol 2005;32:1186-8
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995;123:192-4
   PubMed Web of Science ®Google Scholar
• Healey LA. The relation of giant cell arteritis to polymyalgia rheumatica. Baillieres Clin Rheumatol 1991;5:371-8
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Blanco R, Sanchez-Andrade A, Vazquez-Caruncho M. Giant cell arteritis in Lugo, Spain: a more frequent disease with fewer classic features. J Rheumatol 1997;24:2166-70
   PubMed Web of Science ®Google Scholar
• Rynes RI, Mika P, Bartholomew LE. Development of giant cell (temporal) arteritis in a patient ‘adequately’ treated for polymyalgia rheumatica. Ann Rheum Dis 1977;36:88-90
   PubMed Web of Science ®Google Scholar
• Papadakis MA, Schwartz MD. Temporal arteritis after normalization of erythrocyte sedimentation rate. Arch Intern Med 1986;146:2283-4
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis 2001;60:367-71
   PubMed Web of Science ®Google Scholar
• Rodriguez-Valverde V, Sarabia JM, González-Gay MA, Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med 1997;102:331-6
   PubMed Web of Science ®Google Scholar
• Caselli RJ, Hunder GG. Neurologic aspects of giant cell (temporal) arteritis. Rheum Dis Clin North Am 1993;19:941-53
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Santiago J, Monte R, Blanco R. Low-dose corticosteroids and blindness in giant cell arteritis. Br J Rheumatol 1996;35:702-3
   Google Scholar
• Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998;41:1497-504
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Polymyalgia manifestations in different conditions mimicking polymyalgia rheumatica. Clin Exp Rheumatol 2000;18:755-9
   PubMed Web of Science ®Google Scholar
• Bengston B-A, Malmvall B-E. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum 1981;24:899-904
   PubMedGoogle Scholar
• Spiera H, DAvison S. Long-term follow-up of polymyalgia rheumatica. Mt Sinai J Med 1978;45:225-9
   PubMedGoogle Scholar
• Healey LA, Sheets PK. The relation of polymyalgia rheumatica to rheumatoid arthritis. J Rheumatol 1988;15:750-2
   PubMed Web of Science ®Google Scholar
• Healey LA. Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity. J Rheumatol 1992;19:270-2
   PubMed Web of Science ®Google Scholar
• Bahlas S, Ramos-Remus C, Davis P. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1998;25:99-104
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Macchioni PL, Distal musculoskeletal manifestations in polymyalgia rheumatica. Arthritis Rheum 1998;41:1221-6
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report of nineteen cases. Arthritis Rheum 1996;39:73-80
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Olivieri I, Hunder GG. Polymyalgia rheumatica: a disorder of extraarticular synovial structures. J Rheumatol 1999;26:517-21
   PubMed Web of Science ®Google Scholar
• Salvarani C, Hunder GG. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 1999;42:259-66
   Google Scholar
• Healey LA. Rheumatoid arthritis in the elderly. Clin Rheum Dis 1986;12:173-9
   PubMedGoogle Scholar
• Ceccato F, Roverano S, Barrionuevo A, The role of anticyclic citrullinated peptide antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Clin Rheumatol 2006;25:854-7
   PubMed Web of Science ®Google Scholar
• McCarthy DJ, Oduffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema: RS3PE syndrome. JAMA 1985;254:2763-7
   PubMed Web of Science ®Google Scholar
• Cantini F, Salvarani C, Olivieri I, Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis 1999;58:230-6
   PubMed Web of Science ®Google Scholar
• Dubost J-J, Sauvezie B. Late onset peripheral spondyloarthropathy. J Rheumatol 1989;16:1214-17
   PubMed Web of Science ®Google Scholar
• Olivieri I, Garcia-Porrua C, Padula A, Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases. Rheumatol Int 2007;27:927-33
   PubMed Web of Science ®Google Scholar
• Pego-Reigosa JM, Rodriguez-Rodriguez M, Hurtado-Hernandez Z, Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: a prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms. Arthritis Rheum 2005;5:931-8
   Google Scholar
• Hutton CW, Maddison PJ. Systemic lupus erythematosus presenting as polymyalgia rheumatica in the elderly. Ann Rheum Dis 1986;45:641-4
   PubMed Web of Science ®Google Scholar
• Maragou M, Siotsiou F, Sfondouris H, Late onset systemic lupus erythematosus presentingas polymyalgia rheumatica. Clin Rheumatol 1989;8:91-7
   PubMed Web of Science ®Google Scholar
• Gonzalez-Juanatey C, González-Gay MA, Llorca J, Rheumatic manifestations of infective endocarditis in non-addicts: a 12-year study. Medicine 2001;80:9-19
   PubMed Web of Science ®Google Scholar
• Churchill MA, Geraci HJE, Hunder GG. Musculoskeletal manifestations of bacterial endocarditis. Ann Intern Med 1977;87:754-9
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Ibañez D, Garcia-Pais MJ. Osteoarticular complications of brucellosis in an Atlantic area of Spain. J Rheumatol 1999;26:141-5
   PubMed Web of Science ®Google Scholar
• Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol 2002;29:2143-7
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Lopez-Diaz MJ, Martinez-Lado L, Cancer in biopsy-proven giant cell arteritis. A population-based study. Semin Arthritis Rheum 2007;37:156-63
   PubMed Web of Science ®Google Scholar
• Naschitz SE, Resner I, Rozenbaum M, Cancer-associated rheumatic disorders. Semin Arthritis Rheum 1995;24:231-41
   PubMed Web of Science ®Google Scholar
• Kalra L, Delamere JP. Lymphoreticular malignancy and monoclonal gammopathy presenting as polymyalgia rheumatica. Br J Rheumatol 1987;26:458-9
   PubMedGoogle Scholar
• Ilfeld D, Barzilay J, Vana D, IgG monoclonal gammopathy in four patients with polymyalgia rheumatica. Ann Rheum Dis 1985;44:501
   PubMed Web of Science ®Google Scholar
• von Knorring J. Polymyalgia rheumatica and malignant lymphoma: report on a case. Scand J Rheumatol 1972;1:117-20
   PubMedGoogle Scholar
• Sahin M, Alanoglu G, Aksu O, Hodgkin's lymphoma initially presenting with polymyalgic symptoms: a case report. Mod Rheumatol 2007;17:160-2
   PubMedGoogle Scholar
• Sheon RP, Kirsner AB, Tangsintanapas P, Malignancy in rheumatic disease: interrelationships. J Am Geriatr Soc 1977;25:20-7
   PubMed Web of Science ®Google Scholar
• Von Knorring J, Somer T. Malignancy in association with polymyalgia rheumatica and temporal arteritis. Scand J Rheumatol 1974;3:129-35
   PubMed Web of Science ®Google Scholar
• Sidhom OA, Basalaev M, Sigal LH. Renal cell carcinoma presenting as polymyalgia rheumatica: resolution after nephrectomy. Arch Intern Med 1993;153:2043-5
   PubMedGoogle Scholar
• Salvarani C, Gabriel SE, Gertz MA, Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 1994;37:1621-6
   PubMed Web of Science ®Google Scholar
• Hernández-Rodríguez J, Cid MC, López-Soto A, Treatment of polymyalgia rheumatica. A systematic review. Arch Intern Med 2009;169:1839-50
   PubMedGoogle Scholar
• Hutchings A, Hollywood J, Lamping DL, Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007;57:803-9
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998;37:189-95
   PubMedGoogle Scholar
• Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983;42:374-8
   PubMed Web of Science ®Google Scholar
• Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993;52:847-50
   PubMed Web of Science ®Google Scholar
• Amoli MM, Shelley E, Mattey DL, Intercellular adhesion molecule-1 gene polymorphisms in isolated polymyalgia rheumatica. J Rheumatol 2002;29:502-4
   PubMed Web of Science ®Google Scholar
• Myklebust G, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis: a prospective two-year study in 273 patients. Scand J Rheumatol 2001;30:260-7
   PubMed Web of Science ®Google Scholar
• Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis, I: steroid regimens in the first two months. Ann Rheum Dis 1989;48:658-61
   PubMed Web of Science ®Google Scholar
• Lund B, Egsmose C, Jorgensen S, Krogsgaard MR. Establishment of the relative anti-inflammatory potency of deflazacort and prednisone in polymyalgia rheumatica. Calcif Tissue Int 1987;41:316-20
   PubMed Web of Science ®Google Scholar
• Di Munno O, Imbimbo B, Mazzantini M, Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. J Rheumatol 1995;22:1492-8
   PubMed Web of Science ®Google Scholar
• Krogsgaard MR, Lund B, Johnsson B. A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol 1995;22:1660-2
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Olivieri I, Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol 2000;27:1470-6
   PubMed Web of Science ®Google Scholar
• Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, Can methotrexate be used as a steroid-sparing agent in thetreatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55:218-23
   PubMed Web of Science ®Google Scholar
• Caporali R, Cimmino MA, Ferraccioli G, et al; Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:493-500
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, Salaffi F, De Vita S, Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996;23:624-8
   PubMed Web of Science ®Google Scholar
• De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45:136-8
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Niccoli L, Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 2003;30:760-3
   PubMed Web of Science ®Google Scholar
• Migliore A, Massafra U, Carloni E, TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report. Eur Rev Med Pharmacol Sci 2005;9:373-8
   PubMedGoogle Scholar
• Gabriel SE, Sunku J, Salvarani C, Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997;40:1873-8
   PubMed Web of Science ®Google Scholar
• Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005;64:176-8
   PubMed Web of Science ®Google Scholar
• Oxlund H, Ortoft G, Thomsen JS, The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 2006;39:244-52
   PubMed Web of Science ®Google Scholar